SANDERLING VENTURES MANAGEMENT V 4/A
4/A · ENDOCYTE INC · Filed Jan 11, 2012
Insider Transaction Report
Form 4/AAmended
ENDOCYTE INCECYT
SANDERLING VENTURES MANAGEMENT V
10% Owner
Transactions
- Purchase
Common Stock
2011-12-20$3.20/sh+22,200$71,040→ 52,966 total(indirect: By Sanderling Ventures Management VI) - Purchase
Common Stock
2011-12-21$3.16/sh+22,200$70,152→ 75,166 total(indirect: By Sanderling Ventures Management VI)
Holdings
- 189,003(indirect: By Sanderling Ventures Management V)
Common Stock
Footnotes (5)
- [F1]The form 4 is being amended to correct the number of shares acquired which was incorrectly reported in the original filing.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.14 to $3.27, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
- [F4]Fred Middleton is the owner of Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership.
- [F5]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.10 to $3.21, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.